Relationship between serum angiopoietin-like 4 levels and recurrence of atrial fibrillation

Abstract

Objective

To investigate the association between serum angiopoietin-like 4 (ANGPTL4) levels and recurrence of atrial fibrillation (AF) after catheter ablation.

Methods

This retrospective study recruited patients with AF undergoing catheter ablation and they were divided into two groups (new-onset AF group and recurrent AF group). Demographic, clinical, and laboratory parameters were collected.

Results

A total of 192 patients with AF were included, including 69 patients with recurrence of AF. Serum ANGPTL4 levels were lower in patients with recurrent AF than in those with new-onset AF. Serum ANGPTL4 levels were positively correlated with superoxide dismutase and peroxisome proliferator-activated receptor γ, and negatively correlated with the CHA2DS2-VASC score, left atrial diameter, and levels of brain natriuretic peptide, malondialdehyde, high-sensitivity C-reactive protein, and interleukin-6. The receiver operating characteristic curve showed that the best cut-off for recurrent AF was serum ANGPTL4 levels < 19.735 ng/mL, with a sensitivity and specificity of 63.9% and 74.5%, respectively. Serum ANGPTL4 levels were significantly associated with recurrence and new onset of AF (odds ratio, 2.241; 95% confidence interval, 1.081–4.648).

Conclusions

Serum ANGPTL4 levels are lower in patients with recurrent AF than in those with new-onset AF, and are associated with cardiac hypertrophy, oxidative stress, and inflammation.

Keywords

Atrial fibrillation angiopoietin-like 4 peroxisome proliferator-activated receptor γ cardiac hypertrophy inflammation catheter ablation

Introduction

Atrial fibrillation (AF) is a common persistent and recurrent arrhythmia in clinical practice with an increased risk of stroke and mortality. AF originates in the abnormal atrial matrix and can be triggered and accelerated by multiple disorders, such as heart failure, coronary heart disease, aging, and hypertension.^1,2 The prevalence of AF is high in various medical conditions, such as hypertension, chronic heart failure, atherosclerosis, cardiac hypertrophy, and valvular heart disease.³ Catheter ablation (CA) has been used for treating patients with AF for two decades and has high efficacy compared with antiarrhythmic drugs. However, CA cannot eradicate arrhythmia and recurrence of AF, which are common problems after application of CA.⁴ Many clinical scoring systems can be applied in predicting recurrence of AF after catheter ablation, but they have limited efficacy.⁵ Therefore, new biomarkers of AF are urgently required for their predictive effect on recurrence of AF.

Angiopoietin-like 4 (ANGPTL4) is a stromal cell protein, which is involved in development of many inflammation-related diseases. ANGPTL4 inhibits lipoprotein lipase activity, thus reducing hydrolysis of plasma triglycerides to free fatty acids. ANGPTL4 expression is regulated by fatty acids. Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) strongly enhance ANGPTL4 expression in rat liver cancer cells compared with saturated fatty acids.⁶ Free fatty acids also induce ANGPTL4 expression in cardiomyocytes and show protective function through inhibiting lipoprotein lipase activity.^7,8 Furthermore, ANGPTL4 inhibits phenylephrine-induced cardiac hypertrophy,⁹ which is an important contributor to arrhythmia.¹⁰

In this study, we assessed changes in serum ANGPTL4 levels in patients with AF, and evaluated their association with recurrence of arrhythmia after CA.

Patients and methods

Study population

This retrospective study was carried out in patients with AF from the Department of Cardiology at Zhoupu Hospital between July 2016 and December 2018. This study procedure was examined and approved by the Ethics Committee of Zhoupu Hospital (approval number: WZ-009). Written informed consent was obtained from all patients or their relatives. Patients with AF were diagnosed by an electrocardiogram (ECG)/Holter recording and echocardiography, and all patients had CA performed on admission to hospital. Healthy controls were people who had a physical examination with normal sinus rhythm and no prior history of AF, and they were matched for age and sex. Exclusion criteria were as follows: patients who received anticoagulation treatment within 1 month (e.g., warfarin and dabigatran); patients with valvular heart disease, venous thrombosis, pulmonary embolism, hepatic and renal insufficiency, or cancer; and patients who had surgery and trauma within 1 month. All patients were followed up after CA for at least 3 months, and all patients with AF were treated with anticoagulants during the follow-up. When relapse of arrhythmia occurred within 3 months, the patients were defined as having recurrent AF, and other patients were defined as having new-onset AF.⁴

Radiofrequency CA

A routine blood test, blood biochemistry, coagulation function, myocardial enzyme spectrum, thyroid function, an electrocardiogram, and transthoracic echocardiography were evaluated before the operation. Preoperative transesophageal echocardiography was performed to exclude atrial thrombus. Patients were anesthetized with 1% lidocaine, and the right femoral vein was punctured using the Seldiger technique to establish a pathway. After successful puncture, the LASSO electrode (Biosense Webster, Diamond Bar, CA, USA) and COOLFLEX cryoablation electrode (Abbott, Abbott Park, IL, USA) were inserted into the left atrium from the right atrium through atrioventricular septum puncture. The opening position of the pulmonary veins was determined under the guidance of left atrial modeling, ablation energy and temperature were set to 25 to 35 Watts and 43°C, and cold saline (30°C–35°C) was infused at 17 mL/minute. Fentanyl was used for analgesia and midazolam was used for sedation. Pulmonary vein isolation was performed for CA, with linear ablation of the left and right atria using the superior and inferior pulmonary veins. The end point of CA was bidirectional electrical resistance of the pulmonary vein and left atrium. If AF did not stop during the operation, coronary sinus ablation and fragmentation potential ablation were performed. If AF was still present, synchronous direct current (100–150 J) was applied. At the end of the operation, the sheath tube was pulled out, the bleeding was stopped by compression, and an elastic bandage was applied.

Follow-up

All patients who underwent radiofrequency CA were followed up after discharge. The patients were followed up at 1, 2, 3, 4, 8, and 12 weeks after the operation, and were followed up regularly at 3 and 6 months. All patients at follow-up were asked whether there were any symptoms indicating recurrence of AF. A 12-lead electrocardiogram, dynamic electrocardiogram, and echocardiography were routinely performed, and other relevant examinations were carried out on the basis of the clinical condition of the patients. Patients without palpitation symptoms were routinely examined by ECG or Holter depending on the follow-up date. Patients with palpitation were examined by ECG or Holter immediately. Recurrence of AF was defined as AF, atrial flutter, or atrial tachycardia lasting longer than 30 s after 3 months of radiofrequency ablation.

Clinical data and laboratory tests

Peripheral blood was collected in the morning from each fasting patient on admission to hospital, and samples were sent to a central laboratory as quickly as possible. We recorded the following clinical variables for each patient: age, sex, smoking, hypertension, diabetes mellitus; heart failure, and coronary artery disease. The congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female (CHA2DS2-VASC) score was applied to assess the risk of stroke (congestive heart failure: score of 1; hypertension: score of 1; age of 65–74 years: score of 1; age >75 years: score of 2; diabetes: score of 1; stroke/transient ischemic attack: score of 2; vascular disease: score of 1; female: score of 1). Serum brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, and peroxisome proliferator-activated receptor γ (PPARγ) levels were measured by enzyme-linked immunosorbent assay (ELISA). Serum malondialdehyde (MDA) and superoxide dismutase (SOD) levels were measured by colorimetry.

ELISA detection of serum ANGPTL4 levels

Serum ANGPTL4 levels in controls and in patients with AF were measured by an ELISA kit (cat. no. DY3485; R&D Systems, Minneapolis, MN, USA), and absorbance at 450 nm was measured with a microplate reader (ELx800; Bio-Rad Laboratories, Inc., Hercules, CA, USA). ANGPTL4 levels were calculated using a standard curve, which was established by different levels of recombinant human ANGPTL4, and expressed as ng/mL for each case.

Statistical analysis

Data were analyzed by IBM SPSS version 19.0 (IBM Corp., Armonk, NY, USA) statistical software. Continuous variables are expressed as mean ± standard deviation for a normal distribution or expressed as median (interquartile range) for a non-normal distribution, and were analyzed using the t test or Wilcoxon–Mann–Whitney test. Categorical variables are expressed as frequency (percentage) and were analyzed using the chi-square test. The correlations between ANGPTL4 levels and continuous variables were analyzed using Spearman’s rank correlation test. The receiver operating characteristic curve was constructed to determine the cut-off point of serum ANGPTL4 levels between new-onset AF and recurrent AF. Multivariate logistic regression analysis was performed to determine the effect of low serum ANGPTL4 levels (<19.735 ng/mL) on recurrence of AF, and results are expressed as the odds ratio and the 95% confidence interval. P < 0.05 was considered as a significant difference.

Results

Baseline characteristics

A total of 192 patients with AF who underwent CA ablation were included in this study (mean age: 66.64 ± 11.11 years; 54.2% were men). The follow‐up period was at least 3 months and recurrence of AF occurred in 69 (35.9%) patients. Clinical, echocardiographic, and biochemical data of all patients with AF are shown in Table 1. Patients with recurrence of AF had a higher mean CHA2DS2-VASc score, larger left atrial diameter (LAD), higher serum BNP, MDA, hs-CRP, and IL-6 levels, and lower serum SOD and PPARγ levels compared with those with new-onset AF (all P < 0.05).

Table 1.

Clinical characteristics of patients with newly-diagnosed and recurrent AF.

Variables	New-onset AF (n = 123)	Recurrent AF (n = 69)	χ²/t	P
Age (years)	66.10 ± 12.44	67.59 ± 8.23	0.895	0.372
Male sex	69 (56.1%)	35 (50.7%)	0.514	0.473
BMI (kg/m²)	24.79 ± 2.68	25.64 ± 2.48	2.153	0.033
Smoking	54 (43.9%)	26 (37.7%)	0.704	0.401
CHA2DS2-VASc	2.76 ± 1.38	3.17 ± 1.45	1.978	0.049
Hypertension	55 (44.7%)	29 (42.0%)	0.130	0.719
T2DM	28 (22.8%)	18 (26.1%)	0.268	0.605
HF	24 (19.5%)	24 (34.8%)	5.497	0.019
CAD	24 (19.5%)	18 (26.1%)	1.118	0.290
LVEF (%)	57.84 ± 5.19	59.02 ± 4.99	1.535	0.126
LAD (mm)	42.00 ± 3.42	43.72 ± 3.53	3.299	0.001
BNP (pg/mL)	64.00 ± 11.62	68.96 ± 8.81	3.085	0.002
TG (mmol/L)	2.62 ± 0.48	2.50 ± 0.44	1.725	0.086
TC (mmol/L)	6.08 ± 0.45	5.98 ± 0.43	1.444	0.150
LDL-C (mmol/L)	3.59 ± 0.43	3.50 ± 0.34	1.476	0.141
HDL-C (mmol/L)	1.73 ± 0.35	1.72 ± 0.36	0.270	0.788
MDA (mmol/mL)	7.11 ± 0.89	7.57 ± 0.92	3.345	0.001
SOD (U/mL)	140.30 ± 13.52	137.04 ± 15.70	2.151	0.033
hs-CRP (ng/mL)	6.49 ± 0.90	6.73 ± 0.88	2.076	0.039
IL-6 (pg/mL)	188.61 ± 22.61	200.09 ± 26.59	3.167	0.002
PPARγ (ng/mL)	271.14 ± 37.53	251.95 ± 34.88	3.485	0.001
ANGPTL4 (ng/mL)	20.48 ± 3.57	18.05 ± 3.49	4.708	<0.001

Values are mean ± standard deviation or n (%).

AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65–74 years, female; T2DM, type 2 diabetes mellitus; HF, heart failure; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; BNP, B‐type natriuretic peptide; TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; MDA, malondialdehyde; SOD, superoxide dismutase; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; PPARγ, peroxisome proliferator-activated receptor γ; ANGPTL4, angiopoietin-like 4.

Serum ANGPTL4 levels in patients with recurrent AF

Serum ANGPTL4 levels in patients with AF (19.59 ± 3.57 ng/mL) were significantly lower than those in controls (26.92 ± 3.66 ng/mL, P < 0.001) (Figure 1a). Among patients with AF, serum ANGPTL4 levels were significantly lower in those with recurrent AF than in those with new-onset AF (P < 0.001) (Table 1, Figure 1b).

Figure 1.

Serum ANGPTL4 levels in patients with AF and controls. (a) Serum ANGPTL4 levels were lower in patients with AF (n = 192) than in healthy controls (n = 170). (b) Serum ANGPTL4 levels were lower in patients with recurrent AF (n = 69) than in those with new-onset AF (n = 123). ***P < 0.001

Correlations of serum ANGPTL4 with severity of AF

We performed Spearman’s rank correlation test to determine the associations of ANGPTL4 with clinical and biochemical variables in patients with AF. Serum ANGPTL4 levels were significantly negatively correlated with the CHA2DS2-VASC score, LAD, and BNP, MDA, hs-CRP and IL-6 levels, and positively correlated with serum SOD and PPARγ levels (all P < 0.05, Table 2).

Table 2.

Correlations of serum angiopoietin-like 4 levels with clinical characteristics and biomarker levels in patients with AF.

	r	P
Age (years)	−0.091	0.210
BMI (kg/m²)	−0.186	0.010
CHA2DS2-VASc	−0.148	0.041
LVEF (%)	−0.015	0.833
LAD (mm)	−0.204	0.005
BNP (pg/mL)	−0.205	0.004
TG (mmol/L)	0.008	0.909
TC (mmol/L)	0.055	0.447
LDL-C (mmol/L)	0.097	0.181
HDL-C (mmol/L)	−0.013	0.862
MDA (mmol/mL)	−0.238	0.001
SOD (U/mL)	0.212	0.003
hs-CRP (ng/mL)	−0.144	0.046
IL-6 (pg/mL)	−0.156	0.031
PPARγ (ng/mL)	0.151	0.037

BMI, body mass index; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65–74 years, female; T2DM, type 2 diabetes mellitus; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; BNP, B‐type natriuretic peptide; TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; MDA, malondialdehyde; SOD, superoxide dismutase; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; PPARγ, peroxisome proliferator-activated receptor γ.

Table 3.

Logistic multivariate regression for new-onset and recurrent AF.

Characteristic	Odds ratio	95% confidence interval	P value
LAD (mm)	1.137	1.028–1.258	0.013
BNP (pg/mL)	1.046	1.010–1.084	0.012
MDA (mmol/mL)	1.601	1.077–2.378	0.020
IL-6 (pg/mL)	1.017	1.003–1.031	0.019
PPARγ (ng/mL)	0.988	0.978–0.997	0.012
ANGPTL4 (ng/mL)	2.241	1.081–4.648	0.030

LAD, left atrial diameter; BNP, B‐type natriuretic peptide; MDA, malondialdehyde; IL-6, interleukin-6; PPARγ, peroxisome proliferator-activated receptor γ; ANGPTL4, angiopoietin-like 4.

Serum ANGPTL4 predicts recurrence of AF within 3 months

To differentiate between new-onset and recurrent AF, the receiver operating characteristic curve showed that the cut-off point of serum ANGPTL4 levels was 19.735 ng/mL (sensitivity = 63.9%, specificity = 74.5%; area under the curve = 0.708, P < 0.001) (Figure 2). Multivariate logistic regression analysis showed that various variables, including serum ANGPTL4 (odds ratio, 2.241; 95% confidence interval, 1.081–4.648; P = 0.03) and BNP (odds ratio, 1.046; 95% confidence interval, 1.010–1.084; P = 0.012) levels were independent contributors to recurrence of AF and new-onset AF. Additionally, lower serum ANGPTL4 levels (<19.735 ng/mL) had a significantly higher risk of recurrence (P < 0.001).

Figure 2.

Receiver operating characteristic curve for calculating the area under the curve and the optimal cut-off point for serum ANGPTL4 levels for distinguishing between new-onset and recurrent AF. The optimal cut-off point was 19.735 ng/mL. The AUC was 0.708.

Discussion

This study investigated serum ANGPTL4 levels in patients with AF. We found the following main findings. Patients with AF had significantly lower serum ANGPTL4 levels compared with age- and sex-matched healthy controls. Additionally, serum ANGPTL4 levels were significantly lower in patients with recurrent AF compared with those with new-onset AF. Serum ANGPTL4 levels were negatively correlated with the CHA2DS2-VASC score, LAD, and levels of BNP, MDA, hs-CRP and IL-6, and positively correlated with serum SOD and PPARγ levels in patients with AF. Patients with AF who had lower serum ANGPTL4 levels (<19.735 ng/mL) had a higher risk of recurrence of AF. Therefore, ANGPTL4 may be a good serum biomarker for patients with AF high a risk of recurrence.

The study showed a correlation between serum ANGPTL4 levels and the risk of recurrence of AF. ANGPTL4 is a lipoprotein lipase inhibitor, which reduces hydrolysis of plasma triglycerides to free fatty acids. Enzyme activity of ANGPTL4 is also regulated by negative feedback of fatty acids, thus maintaining a steady state.¹¹ This indicates that ANGPTL4 expression is increased by fatty acids, especially by polyunsaturated fatty acids in liver cancer cells and in cardiomyocytes.^6,7 Patients with AF show disorder of fatty acid metabolism and a change in atrial fatty acid transport, which is thought to be related to an increased risk of AF attack after a heart operation.¹² Additionally, patients with AF show increased saturated fatty acids and decreased polyunsaturated fatty acids in plasma, suggesting that free fatty acids may be involved in development and progression of AF.¹³ A series of in vitro and animal and clinical studies showed that omega-3 polyunsaturated fatty acids (ω-3 PUFAs) had a preventive effect on arrhythmia as follows. Previous studies have shown that ω-3 PUFAs have preventive efficacy in cardiovascular disease by reducing plasma lipids, although their preventive effect on AF is unclear.¹⁴ Research on cardiomyocytes in vitro and in animal models has clarified many mechanisms of the antiarrhythmic effect of ω-3 PUFAs in AF, including electrophysiological, anti-inflammatory, and anti-fibrotic mechanisms, and regulation of sympathetic vagal balance.¹⁵ However, the clinical efficacy of ω-3 PUFAs in patients with AF is controversial. Additionally, the risk of AF was not reduced or even increased by ω-3 PUFA treatment in two recently published reports.^16,17 Therefore, the mechanism of action of ω-3 PUFAs is complex, and pathological factors (e.g., increased risk of bleeding) and protective factors exist simultaneously. Our study showed reduced serum ANGPTL4 levels in patients with AF compared with healthy controls. Therefore, whether fatty acids are a mediator or inducer of ANGPTL4 in AF is unclear, and how fatty acids participate in the occurrence and maintenance of AF remains unclear. Human plasma ANGPTL4 levels can be increased by caloric restriction and exercise via elevated free fatty acids.¹⁸ However, the detailed mechanisms of ANGPTL4 in AF should be investigated at the cellular and molecular levels.

We found an association of ANGPTL4 with cardiac hypertrophy, as shown by negative correlations of serum ANGPTL4 levels with LAD and BNP levels, which are three important indicators of cardiac hypertrophy. Serum BNP levels are increased in patients with AF and increased atrial pressure,¹⁹ and they are regarded as an independent predictor of recurrence of AF.²⁰ Our study supports the above-mentioned results because we found markedly higher serum BNP levels in recurrent AF compared with new-onset AF. Multivariate analysis also showed that serum BNP levels were an independent predictor for recurrence of AF. This finding supports the hypothesis that hypertrophy involves progression and recurrence of AF.^21,22 A previous study showed that ANGPTL4 had an inhibitory effect on cardiomyocyte hypertrophy.⁹ Whether ANGPTL4 modulates cardiomyocyte hypertrophy in AF is unclear and requires further investigation.

Our study showed that serum PPARγ levels were lower in recurrent AF compared with new-onset AF, and they were positively correlated with ANGPTL4. Transcription and expression of ANGPTL4 are directly regulated by peroxisome proliferator-activated receptors (PPARs), such as PPARα, PPARβ/δ, and PPARγ.²³ PPARα and PPARγ are related to AF. Elderly patients with AF show an inflammatory status and atrial remodeling, and lower serum PPARγ protein levels.²⁴ In a rat model, the PPARγ activator pioglitazone prevents age-related AF susceptibility by increasing antioxidant capacity and reducing apoptosis.²⁵ PPARγ activators also inhibit cardiac fibrosis caused by diabetes, hypertension, and AF.²⁶ Atrial PPARα tissue expression is reduced in patients with AF and is associated with atrial metabolic remodeling.²⁷ ANGPTL4 also inhibits cardiac hypertrophy by enhancing PPARα expression.⁹ Our study indicates that PPARγ is an independent predictor for recurrence of AF. Whether PPARα and PPARγ modulate ANGPTL4 and related mechanisms in AF are unknown.

Limitations of this study are as follows. First, the source of serum ANGPTL4 in patients with AF is still unclear. Whether ANGPTL4 is derived from cardiomyocytes requires further study, and this should be verified in excised myocardial tissue of patients with AF and valvular heart disease. Second, in this study, serum ANGPTL4 levels were measured only at the beginning of admission, and detailed time series of serum ANGPTL4 levels after admission and recurrence were lacking. Third, an animal model is required to determine the possible mechanisms of ANGPTL4 in the pathophysiology of AF. Fourth, ANGPTL4 expression can be affected by many factors, such as PPARγ. Therefore, whether serum ANGPTL4 can be upregulated by PPARγ activators should be investigated in clinical studies and animal models.

In conclusion, serum ANGPTL4 levels are decreased in patients with recurrent AF, and are associated with cardiac hypertrophy, oxidative stress, inflammation, and serum PPARγ levels. Serum ANGPTL4 levels are an independent predictor for recurrence of AF, and might act as a biomarker for predicting recurrence of arrhythmia post‐CA.

Footnotes

Availability of data and materials

The raw data used and analyzed for the current study are available from the corresponding author on reasonable request.

Author contributions

Zhongping Ning conceived the idea of the study, designed and supervised the study, and wrote the manuscript. Xinming Li designed the study and wrote the manuscript. Xi Zhu collected clinical data and performed statistical analysis. Jun Luo and Yingbiao Wu performed the experiments. All authors have read and approved the manuscript.

Declaration of conflicting interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by (1) the Clinical Plateau Discipline of Pudong New Area Health Committee (Grant No: PWYgy2018-03); (2) the Key Specialty Construction Project of Pudong New District Health Committee (Grant No: PWZzk2017-19); and (3) the General Project of Science and Technology Committee of Pudong New Area (Grant No: PKJ2019-Y40).

ORCID iD

Zhongping Ning

References

Gutierrez

Van Wagoner

DR.

Oxidant and inflammatory mechanisms and targeted therapy in atrial fibrillation: an update.

J Cardiovasc Pharmacol 2015; 66: 523–529.

Thanigaimani

Lau

Agbaedeng

, et al. Molecular mechanisms of atrial fibrosis: implications for the clinic. Expert Rev Cardiovasc Ther 2017; 15: 247–256.

Andrade

Khairy

Dobrev

, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114: 1453–1468.

Calkins

Hindricks

Cappato

, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14: e275–e444.

Deng

Bai

Shantsila

, et al. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin Res Cardiol 2017; 106: 813–823.

Brands

Sauerwein

Ackermans

, et al. Omega-3 long-chain fatty acids strongly induce angiopoietin-like 4 in humans. J Lipid Res 2013; 54: 615–621.

Georgiadi

Boekschoten

Müller

, et al. Detailed transcriptomics analysis of the effect of dietary fatty acids on gene expression in the heart. Physiol Genomics 2012; 44: 352–361.

Puthanveetil

Wan

Rodrigues

Lipoprotein lipase and angiopoietin-like 4 - Cardiomyocyte secretory proteins that regulate metabolism during diabetic heart disease.

Crit Rev Clin Lab Sci 2015; 52: 138–149.

Sun

Liu

, et al. The Role of Angiopoietin-like Protein 4 in Phenylephrine-induced Cardiomyocyte Hypertrophy. Biosci Rep 2019; 39: pii: BSR20171358.

10.

Chatterjee

Bavishi

Sardar

, et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol 2014; 114: 1049–1052.

11.

Robal

Larsson

Martin

, et al. Fatty acids bind tightly to the N-terminal domain of angiopoietin-like protein 4 and modulate its interaction with lipoprotein lipase. J Biol Chem 2012; 287: 29739–29752.

12.

Shingu

Yokota

Takada

, et al. Decreased gene expression of fatty acid binding protein 3 in the atrium of patients with new onset of atrial fibrillation in cardiac perioperative phase. J Cardiol 2018; 71: 65–70.

13.

Jung

Cho

Kim

, et al. Lipidomic profiling reveals free fatty acid alterations in plasma from patients with atrial fibrillation. PLoS One 2018; 13: e0196709.

14.

Colussi

Catena

Fagotto

, et al. Atrial fibrillation and its complications in arterial hypertension: The potential preventive role of ω-3 polyunsaturated fatty acids. Crit Rev Food Sci Nutr 2019; 59: 1937–1948.

15.

Nodari

Triggiani

Campia

, et al. Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. J Atr Fibrillation 2012; 5: 718.

16.

Kalstad

Myhre

Laake

, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial. Circulation 2020 Nov 15. Epub ahead of print.

17.

Sheikh

Vande Hei

Battisha

, et al. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol 2019; 18: 84.

18.

Kersten

Lichtenstein

Steenbergen

, et al. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol 2009; 29: 969–974.

19.

Fan

Cao

, et al. NT‐proBNP, but not ANP and C‐reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation. J Interv Card Electrophysiol 2012; 33: 93–100.

20.

Lewicka

Dudzińska-Gehrmann

Dąbrowska-Kugacka

, et al. Plasma biomarkers as predictors of recurrence of atrial fibrillation. Pol Arch Med Wewn 2015; 125: 424–433.

21.

Wang

Dong

, et al. Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation. Clin Cardiol 2018; 41: 797–802.

22.

Erküner

Dudink

EAMP

Nieuwlaat

, et al. Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). Am J Cardiol 2018; 122: 578–583.

23.

La Paglia

Listì

Caruso

, et al. Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. PPAR Res 2017; 2017: 8187235.

24.

Lin

Jia

Sun

A pilot study of circulating PPAR-γ receptor protein in elderly patients with atrial fibrillation. Arch Med Sci 2012; 8: 471–476.

25.

Murakoshi

Igarashi

, et al. PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012; 23: 209–217.

26.

Liu

Liao

Yang

, et al. Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis. PPAR Res 2016; 2016: 2198645.

27.

Liu

Hou

Yuan

, et al. Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway. Br J Pharmacol 2016; 173: 1095–1109.